公开(公告)号：US20200093588A1

公开(公告)日：2020-03-26

申请号：US16140801

申请日：2018-09-25

申请人： Lisa Brothers Arbisser ,  Gholam Peyman

发明人： Lisa Brothers Arbisser ,  Gholam Peyman

IPC分类号： A61F2/16 ,  A61F9/007 ,  A61F9/008

摘要： An intraocular lens has central lens body at least one haptic extending from the central lens body. The haptic has a lobular configuration. The lens body and the haptic having a folded configuration for implantation within the eye. The lens having a first deployed configuration wherein the lens body is positioned at a location substantially behind sealed anterior and posterior portions of the lens capsule with the at least one haptic positioned at a location substantially over top of the sealed anterior and posterior portions of the lens capsule. The lens having a second deployed configuration wherein the lens body is positioned at a location substantially in front of the sealed anterior and posterior portions of the lens capsule with the at least one haptic positioned at a location substantially over behind the sealed anterior and posterior portions of the lens capsule.

公开(公告)号：US20120089021A1

公开(公告)日：2012-04-12

申请号：US13066012

申请日：2011-04-04

申请人： Gholam Peyman

发明人： Gholam Peyman

IPC分类号： A61B8/10 ,  A61N5/067 ,  A61B6/00 ,  A61N7/00

CPC分类号： A61B8/085 ,  A61B8/10 ,  A61B8/14 ,  A61B8/4444 ,  A61B8/4477 ,  A61B8/483 ,  A61B8/5253 ,  A61B2018/00321 ,  A61B2090/378 ,  A61F9/008 ,  A61N7/02

摘要： An ultrasonic scanning apparatus that includes a unique ultrasonic array to transmit ultrasonic energy to a biological structure, such as an eye. The ultrasonic array provides specific three-dimensional (3-D) information relating to the eye and precise volumetric information relating to structures associated therewith, such as a tumor, prior, during and/or after treatment. The ultrasonic array can also be combined with a therapeutic ultrasonic unit for real-time 3-D observation of a structure and the focal point of the transmitted therapeutic beam(s) on a monitor during the treatment of a structure, e.g., treatment of a lesion.

摘要翻译： 一种超声波扫描装置，其包括用于将超声波能量传输到诸如眼睛的生物结构的唯一超声波阵列。 超声波阵列提供与眼睛相关的特定三维（3-D）信息和与其相关的结构如肿瘤，治疗前，治疗期间和/或之后有关的精确体积信息。 超声波阵列还可以与治疗性超声波单元组合，用于在结构治疗期间对监测器上的结构和透射治疗束的焦点进行实时3-D观察，例如治疗 病变。

公开(公告)号：US20100049447A1

公开(公告)日：2010-02-25

申请号：US12583466

申请日：2009-08-21

申请人： Gholam Peyman ,  Eniko Todorov Enikov

发明人： Gholam Peyman ,  Eniko Todorov Enikov

IPC分类号： G06F19/00 ,  G06G7/48 ,  G01M19/00

CPC分类号： G16H50/50 ,  A61B3/0025

摘要： A method for simulating the behavior of an eye comprising the steps of (i) generating a FEM model of the eye representing the physical structure of the eye, the FEM model including an elastic walled corneo-scleral shell, (ii) modeling deformations of the eye with the FEM model, the deformation modeling including the simulated application of at least one external force to the FEM model, and (iv) obtaining FEM model solutions iteratively in an incremental fashion, whereby adjustable nodal pressure is introduced inside the corneo-scleral shell.

摘要翻译： 一种用于模拟眼睛行为的方法，包括以下步骤：（i）产生代表眼睛的物理结构的眼睛的FEM模型，包括弹性围壁的巩膜外壳的FEM模型，（ii）模型的变形 通过FEM模型，变形建模包括对FEM模型的至少一个外力的模拟应用，以及（iv）以递增的方式迭代地获得FEM模型解，从而在角膜巩膜内引入可调节节点压力 。

公开(公告)号：US20080102101A1

公开(公告)日：2008-05-01

申请号：US11931938

申请日：2007-10-31

申请人： Gholam Peyman

发明人： Gholam Peyman

IPC分类号： A61K9/00 ,  A61K38/13 ,  A61P27/02

CPC分类号： A61K31/192 ,  A61K31/365 ,  A61K31/436 ,  A61K31/56 ,  A61K31/60 ,  A61K31/7048 ,  A61K38/13 ,  A61K38/185 ,  A61K38/204 ,  A61K38/2093 ,  A61K2300/00

摘要： An ocular method comprising localized ocular administration of a pharmaceutically acceptable formulation and effective concentration of at least one neuro-stimulatory agent, which may include a macrolide, for a duration sufficient to at least partially restore corneal sensation, or at least one macrolide to reduce scarring after ocular surgery. The neuro-stimulatory agent may be one or more of a macrolide, macrolide analog, neurotrophin, or neuropoietic factor. The method is used in a patent following ocular surgery, such as vision-correction surgery, glaucoma surgery, or retinal detachment repair surgery.

摘要翻译： 一种眼睛方法，其包括局部眼睛施用药学上可接受的制剂和有效浓度的至少一种神经刺激剂，其可以包括大环内酯，持续时间足以至少部分地恢复角膜感觉，或至少一种大环内酯以减少瘢痕形成 眼手术后。 神经刺激剂可以是大环内酯类，大环内酯类似物，神经营养蛋白或神经生成因子中的一种或多种。 该方法用于眼外科手术后的专利，例如视力矫正手术，青光眼手术或视网膜脱离修复手术。

公开(公告)号：US20070100443A1

公开(公告)日：2007-05-03

申请号：US11259781

申请日：2005-10-27

申请人： Gholam Peyman

发明人： Gholam Peyman

IPC分类号： A61F2/16

CPC分类号： A61F2/1635 ,  A61F2/145 ,  A61F2/1627 ,  A61F2250/0002 ,  G02B3/14

摘要： A lens system is provided. The lens system can include a lens adapted to be part of the optical pathway of an eye and a sensor. The sensor is adapted to sense a condition. The lens system also includes a control unit. The control unit is adapted to receive a signal from the sensor. The signal includes information about the condition. The control unit is operable to alter the shape of the lens based at least partly upon the condition. The lens can be adapted for positioning inside the capsular bag of the eye, in the posterior chamber of the eye, in place of the capsular bag of the eye or in the cornea. The sensor can be a tension sensor. The condition can be the amount of tension at the zonules of the eye. The control system can include a fluidic pressure generator and a fluid flow control device.

摘要翻译： 提供透镜系统。 透镜系统可以包括适于作为眼睛和传感器的光学路径的一部分的透镜。 该传感器适于感测一种状况。 透镜系统还包括控制单元。 控制单元适于从传感器接收信号。 信号包括有关条件的信息。 控制单元可操作以至少部分地基于条件改变透镜的形状。 透镜可以适用于定位眼睛的囊袋内，眼睛的后室，代替眼袋或角膜中的囊袋。 传感器可以是张力传感器。 这种情况可以是眼睛附属区域的张力。 控制系统可以包括流体压力发生器和流体流量控制装置。

公开(公告)号：US20070088415A1

公开(公告)日：2007-04-19

申请号：US11558788

申请日：2006-11-10

申请人： Gholam Peyman

发明人： Gholam Peyman

IPC分类号： A61F7/00

CPC分类号： A61F7/02 ,  A61F9/008 ,  A61F9/00821 ,  A61F2007/0004 ,  A61F2009/00853 ,  A61F2009/00863 ,  A61F2009/00872 ,  A61F2009/00891 ,  A61F2009/00895

摘要： The present invention relates to a device for treating the eye, including a body portion configured to be positioned adjacent the exterior surface of the cornea and a heating means for heating the body portion to a predetermined temperature to affect at least one of the following: facilitation of the escape of aqueous humor from the eye and substantially preventing coagulation of the corneal tissue, while substantially destroying tumor cells.

摘要翻译： 本发明涉及一种用于治疗眼睛的装置，包括构造成邻近角膜外表面定位的主体部分和用于将身体部分加热到预定温度的加热装置，以影响以下至少一个：促进 的房水从眼睛逃脱，并且基本上防止角膜组织的凝结，同时基本上破坏肿瘤细胞。

公开(公告)号：US20070072933A1

公开(公告)日：2007-03-29

申请号：US11348465

申请日：2006-02-06

申请人： Gholam Peyman

发明人： Gholam Peyman

IPC分类号： A61K31/404

CPC分类号： A61K31/404 ,  A61K9/0048

摘要： A method to ameliorate age related macular degeneration or another disease of fluid leakage from new ocular blood vessels to a surrounding area, by administering sunitinib maleate. In one embodiment, sunitinib maleate is administered without photodynamic or laser coagulation therapy. In one embodiment, sunitinib maleate is administered in conjunction with photodynamic or laser coagulation therapy.

摘要翻译： 一种通过施用马来酸舒尼替尼来改善年龄相关性黄斑变性或另一种从新眼睛血管渗漏到周围区域的疾病。 在一个实施方案中，在没有光动力学或激光凝血治疗的情况下施用马来酸舒尼替尼。 在一个实施方案中，马来酸舒尼替尼与光动力学或激光凝血治疗联合给药。

公开(公告)号：US20070031471A1

公开(公告)日：2007-02-08

申请号：US11425017

申请日：2006-06-19

申请人： Gholam Peyman

发明人： Gholam Peyman

IPC分类号： A61F2/00

CPC分类号： A61L27/3683 ,  A61L27/3604 ,  A61L27/3641

摘要： Amniotic membranes provided as emulsions to provide desirable features. The emulsion, containing micron or submicron sized particles of amniotic membrane, is formulated to increase absorption and overall bioavailability. In one embodiment, the emulsion is sprayed onto an implantable or insertable medical device. In another embodiment, the emulsion is sprayed onto an ocular surface or inserted in or on an ocular device in an individual having or at risk for developing dry eye.

摘要翻译： 羊膜提供为乳液以提供所需特征。 含有微米或亚微米尺寸的羊膜颗粒的乳液经配制以增加吸收和总体生物利用度。 在一个实施方案中，将乳剂喷涂到可植入或可插入的医疗装置上。 在另一个实施方案中，将乳液喷雾到眼表面上或者插入到具有或具有发展干眼风险的个体中的眼睛装置中或其上。

公开(公告)号：US07083802B2

公开(公告)日：2006-08-01

申请号：US10631143

申请日：2003-07-31

申请人： Gholam Peyman

发明人： Gholam Peyman

IPC分类号： A61F13/00 ,  A61F2/00 ,  A61K9/00

CPC分类号： A61K31/4745 ,  A61K9/0051 ,  A61K31/33

摘要： A formulation to treat ocular conditions such as dry eye disease, as well as other conditions, is disclosed. Rapamycin and/or ascomycin is administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye. For example, a topical administration may contain between about 50 pg/ml drug to about 50 μg/ml drug in a formulation which may be applied at bedtime or throughout the day. For injection, a dose of about 50 pg/ml to about 200 μg/ml may be used. Rapamycin and/or ascomycin may also be administered in milligram quantities as a surgical implant, for example, in a diffusible walled reservoir sutured to the wall of the sclera, or may be contained within an inert carrier such as microspheres or liposomes to provide a slow-release drug delivery system.

摘要翻译： 公开了用于治疗眼部疾病如干眼病以及其他病症的制剂。 眼内注射雷帕霉素和/或子囊霉素，例如通过局部施用，注射到眼睛中，或植入在眼中或眼睛上。 例如，局部给药可以在睡前或全天施用的制剂中含有约50pg / ml的药物与约50μg/ ml的药物。 对于注射，可以使用约50pg / ml至约200ug / ml的剂量。 雷帕霉素和/或子囊霉素也可以以毫克量施用作为手术植入物，例如缝合在巩膜壁上的可扩散壁的储存器中，或者可以包含在惰性载体如微球或脂质体中以提供缓慢 - 释放药物输送系统。

公开(公告)号：US20060134066A1

公开(公告)日：2006-06-22

申请号：US11021198

申请日：2004-12-22

申请人： Gholam Peyman

发明人： Gholam Peyman

IPC分类号： A61K9/127 ,  A61K9/14 ,  A61K48/00

CPC分类号： A61K48/0008 ,  A61K48/0041

摘要： Methods are disclosed to enhance controlled localization and/or release of an agent at an anatomical and/or physiological site where the agent is desirable. In one embodiment, the method localizes vector transfected with a gene(s) that enhances neovascularization (i.e., genes encoding angiogenic agents). In another embodiment, the method localizes genes that inhibit neovascularization (i.e., genes encoding antiangiogenic agents) at sites where new blood vessel growth is undesirable. The vector is provided in a biocompatible substance substantially preventing migration of the vector from the site in need of therapy. The substance may be a matrix, gel, a polymer, liposome, capsule, nanoparticle, microparticle. The substance may form in situ, for example, a fibrin entraining mesh or network form from fibrinogen and thrombin.

摘要翻译： 公开了增强药剂在所需药剂的解剖和/或生理部位的受控定位和/或释放的方法。 在一个实施方案中，该方法定位用增强新生血管形成的基因（即编码血管生成剂的基因）转染的载体。 在另一个实施方案中，该方法将抑制新生血管形成的基因（即，编码抗血管生成剂的基因）定位在新血管生长不期望的部位。 该载体提供在生物相容性物质中，基本上防止载体从需要治疗的部位迁移。 该物质可以是基质，凝胶，聚合物，脂质体，胶囊，纳米颗粒，微粒。 该物质可以原位形成，例如纤维蛋白原和凝血酶引起的纤维蛋白夹带网或网络形式。